Tysabri and PML: What Patients Should Know About Risk and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Legal Guidance

If you or a loved one has taken Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Understanding how medication duration, prior immunosuppressant use, and JC virus exposure affect risk is critical. The medical community has long emphasized the importance of balancing therapeutic benefits with potential adverse events, and this page provides a clear overview of the key factors that influence PML risk for Tysabri users.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative integrates clinical, pharmacological, and risk-related evidence to inform patients and their legal representatives. Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system that results from reactivation of the JC virus in immunocompromised individuals. Clinical presentation typically includes progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JC virus. The drug's pharmacology directly increases the risk of PML by allowing unchecked viral replication in the brain. In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Context and Legal Implications for North Carolina Patients

The FDA Adverse Event Reporting System (FAERS) data show that fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder are among the most frequently reported adverse events associated with Tysabri, though PML is a less common but devastating outcome (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. The warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, the drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed consent and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers fully understand the magnitude of risk, especially in the context of long-term therapy. For patients who develop PML after Tysabri exposure, attorney-related considerations are important. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for careful documentation of treatment duration, JC virus antibody status, and any prior immunosuppressant use. Legal claims may focus on whether the warnings provided were sufficient to allow informed decision-making, particularly regarding the risk of PML and its often fatal or disabling outcome. In summary, Tysabri-associated PML is a serious adverse event with a clear mechanistic link to the drug's immunomodulatory effects. The FDA-mandated boxed warning and restricted distribution program aim to mitigate risk, but affected patients may still face severe harm. For those considering legal action, evidence of risk factors, treatment duration, and the adequacy of warnings will be central to any claim. Patients in North Carolina who have experienced PML after Tysabri use should consult with an attorney experienced in pharmaceutical injury cases to evaluate their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug impairs immune surveillance, allowing viral replication in the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do North Carolina patients have if they developed PML after Tysabri?

Patients may pursue claims focusing on inadequate warnings or negligence. Legal action requires documentation of treatment duration, JC virus antibody status, and prior immunosuppressant use. Consulting an attorney experienced in pharmaceutical injury is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.